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Aims To determine the optimal T1 mapping approach to assess myocardial fibrosis at 3T.
Methods
and results
T1 mapping was performed at 3T using the modified look-locker-inversion sequence in 20 healthy volunteers and 20
patients with aortic stenosis (AS). Pre- and post-contrast myocardial T1, the partition coefficient (l; DRmyocardium/
DRblood, where DR ¼ 1/post-contrast T12 1/pre-contrast T1), and extracellular volume fraction [ECV; l (1 2
haematocrit)] were assessed. After establishing the optimal time point and myocardial region for analysis, we compared
the reproducibility of these T1 measures and their ability to differentiate asymptomatic patients with AS from healthy
volunteers. There was no segmental variation across the ventricle in any of the T1 measures evaluated. l and ECV did
not vary with time, while post-contrast T1 was relatively constant between 15 and 30 min. Thus, mid-cavity myocardium
at 20 min was used for subsequent analyses. ECV displayed excellent intra-, inter-observer, and scan–rescan reprodu-
cibility [intra-class correlation coefficients (ICC) 1.00, 0.97, and 0.96, respectively], as didl (ICC 0.99, 0.94, 0.93, respect-
ively). Moreover, ECV and l were both higher in patients with AS compared with controls (ECV 28.3+1.7 vs.
26.0+ 1.6%, P, 0.001; l 0.46+0.03 vs. 0.44+ 0.03, P ¼ 0.02), with the former offering improved differentiation. In
comparison, scan–rescan reproducibilities for pre- and post-contrast myocardial T1 were only modest (ICC 0.72 and
0.56) with no differences in values observed between cases and controls (both P . 0.05).
Conclusions ECV appears to be the most promising measure of diffuse myocardial fibrosis at 3T based upon its superior reproducib-
ility and ability to differentiate disease from health.
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Introduction
Myocardial fibrosis is a common pathological finding in a wide range
of cardiovascular diseases and has been associated with an adverse
prognosis.1 –3 Using cardiovascular magnetic resonance (CMR), the
late gadolinium enhancement (LGE) technique has become widely
used to evaluate focal myocardial fibrosis. However in many condi-
tions, including aortic stenosis, a more diffuse form of fibrosis pre-
dominates, which crucially is reversible and therefore a potential
target for novel therapeutic strategies.4– 7 LGE imaging has inherent
limitations in assessing diffuse fibrosis because it relies upon detecting
a difference in signal intensity between normal and fibrotic regions.8
Consequently, it has difficulty in discriminating areas of diffuse
myocardial fibrosis, which tend to have an even distribution.
Recently, several T1 mapping approaches have been developed to
quantify diffuse fibrosis. The first approach measures intrinsic myo-
cardial T1 on the basis that T1 relaxation times are longer in
regions of fibrosis (pre-contrast T1).9– 11 Alternatively, myocardial
T1 can be measured following gadolinium administration, which
accumulates in fibrotic areas on account of the increased extracellu-
lar volume (post-contrast T1).12,13 However, post-contrast T1 is
potentially confounded by individual variations in gadolinium kinetics
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and by the precise timing of imaging.8 As a result, investigators
have proposed methods to correct for these factors using either
blood-pool T1 values to derive the partition coefficient (l),14 or
plasma volume to calculate the contrast volume of distribution in
the myocardium. The latter is commonly referred to as the myocar-
dial extracellular volume fraction (ECV).15–20 Each of these
approaches have been validated against the extent of myocardial
fibrosis on histology.12,13,15,17,18,20 However, the optimal technique
remains uncertain due to a lack of consistent acquisition sequences
and disease states studied, whilst direct comparative studies are rela-
tively lacking.20 In addition, there is insufficient reproducibility data
(particularly scan–rescan) and few studies have been performed at
3T,21 –24 which may offer potential improvements compared with
1.5T.25
Therefore, the purpose of this study was to perform a systematic
and comprehensive assessment to determine the optimal T1 ap-
proach at 3T. In particular, we aimed to characterize the temporal
and regional T1 profiles of the myocardium and to identify the
optimal technique based upon its reproducibility and ability to differ-
entiate asymptomatic patients with aortic stenosis from healthy
volunteers. Patients with advanced symptoms and focal scarring
were excluded so as to focus on patients in whom diffuse myocardial
fibrosis is most likely to be of clinical interest.
Methods
Study participants
Twenty asymptomatic patients with mild-to-severe aortic stenosis were
recruited from outpatient clinics at the Edinburgh Heart Centre (see
Supplementary data online). Twenty healthy volunteers were recruited
from the community and the University of Edinburgh. All individuals
had normal renal function and a left ventricular ejection fraction within
the normal range.
The exclusion criteria for patients with aortic stenosis were as follows:
(i) other significant valvular heart disease (moderate to severe in nature),
(ii) acquired or inherited cardiomyopathies, (iii) previous myocarditis
and (iv) the presence of focal LGE. The exclusion criteria for healthy
volunteers were as follows: (i) hypertension, (ii) diabetes mellitus, (iii)
coronary artery disease (previous myocardial infarction, evidence of
myocardial ischaemia, or .50% luminal stenosis in a major epicardial
vessel) (iv) valvular heart disease, (v) cardiomyopathy or previous
myocarditis, and (vi) the presence of focal LGE.
All clinical assessments and imaging studies were carried out at the
Wellcome Trust Clinical Research Facility and the Clinical Research
Imaging Centre, Edinburgh. Studies were performed with the approval
of the local research ethics committee, and with the written informed
consent from each participant.
Imaging protocols
Echocardiography
Transthoracic echocardiography was performed in all participants (iE33,
Philips Medical Systems, The Netherlands) by two independent opera-
tors. The severityof aortic stenosiswasclassifiedusing aortic valve jet vel-
ocity, mean pressure gradient, and the aortic valve area, according to the
American Heart Association/American College of Cardiology guide-
lines.26 Diastolic function was assessed using pulse-wave Doppler
[early (E) and late (A) mitral inflow velocities] and tissue Doppler
imaging (average of medial and lateral annulus velocities of the mitral
valve, e′).
CMR imaging
CMR was performed at 3T (MAGNETOM Verio, Siemens AG, Health-
care Sector, Erlangen, Germany) according to the study protocol (Sup-
plementary data online). Short-axis cine images were obtained using a
balanced steady-state free precession sequence (8-mm parallel slices
with 2-mm spacing) for the assessment of left ventricular function and
volumes.
T1 mapping was performed using the MOdified Look-Locker Inver-
sion recovery (MOLLI; flip angle 358; minimum TI 100 ms; TI increment
of 80 ms; time delay of 150 ms with a heart beat acquisition scheme of
3-3-5) with built-in motion correction.27 A gradient echo field map and
associated shim were performed to minimize off-frequency artefact.
Short-axis T1 maps of the mid-cavity slice were acquired in diastole
before and at 2, 5, 10, 15, 20, and 30 min following the administration
of 0.1 mmol/kg of gadobutrol (Gadovist/Gadavist, Bayer Pharma AG,
Germany). Additional basal and apical T1 maps were obtained in diastole
at 0, 15, 20, and 30 min (see Supplementary data online). The basal slice
was defined as the first complete ring of myocardium below the aortic
outflow tract, and the mid-cavity slice as the most basal slice to include
both papillary muscles. The apical slice was selected between the apex
and the mid-cavity on the image least affected by trabeculations and
partial volume averaging.
LGE imaging was performed between 8 and 15 min using two
approaches: an inversion-recovery fast gradient-echo sequence and a
phase-sensitive inversion recovery sequence, performed in two phase-
encoding directions to differentiate true enhancement from
artefact.28,29 The inversion time was optimized for each slice to achieve
satisfactory nulling of the myocardium.
Imaging analysis
Assessment of the left ventricle and myocardial
enhancement
The quantification of left ventricular function, volumes, and mass was
performed using the Argus Ventricular Function software (Siemens AG
Healthcare Sector). All volumes and mass were indexed to body
surface area. Qualitative assessment of myocardial enhancement was
assessed independently by two experienced operators (M.D. and S.M.).
Assessing the quality of T1 maps
The quality of T1 map data was examined using the individual inversion
recovery images. All segments affected by off-resonance, excessive
breathing motion artefacts not corrected by the inline motion correc-
tion, and mistriggering were excluded from the analysis.
Assessing myocardial T1 at multiple time points
Myocardial T1 values were assessed at multiple time points to establish
the optimal time point for post-contrast T1 mapping. This was defined
at the flattest point on the T1 relaxation curve at which variation in T1
values with time was at a minimum. Mid-cavity motion-corrected T1
maps were analysed using a dedicated workstation (OsiriX version
4.1.1, Geneva, Switzerland). To minimize partial volume effects from
surrounding tissues and blood pool, we standardized the windowing
and placement of regions of interest (ROI) around the mid-cavity myo-
cardium using a pre-defined protocol (Figure 1). The ROI were first
drawnon the pre-contrastT1maps and then copiedontoeachof thecor-
responding post-contrast T1 maps with stringent adjustments applied to
avoid blood pool and artefact (Figure 1A). This approach ensured consist-
ency in the placement of ROI across the different time points, allowing us
to investigate the temporal variation in our T1 measures.
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Figure 1 Methodology for measuring myocardial T1 at multiple time points and in multiple segments of the left ventricle (A) Measurement of
myocardial T1 at multiple time points. ROI were drawn within the borders on the pre-contrast myocardial T1 maps and then copied onto the cor-
responding post-contrast images at all time points. Minor adjustments were made to avoid artefact and blood pool. An ROI was also drawn in the left
ventricular blood pool in order to calculate the partition coefficient (l) and extracellular volume fraction (ECV) at each time point. This approach
demonstratedexcellent intra- and inter-observer reproducibility. (B)Assessmentof regional variation inT1measures.Using the anteriorand inferior
ventricular insertion points as well as the mid-point of the ventricular cavity as reference points, three intersecting lines were drawn to divide the left
ventricle into 16 segments. ROI were drawn onto the basal (six segments), mid-cavity (six segments), and apical (four segments) pre-contrast T1
maps with the standardized approach described above. Subsequently, the ROI were copied onto the 20-min post-contrast T1 maps. Pre- and post-
contrast T1, l, and ECV values were assessed in each segment
T1 mapping at 3T in patients with AS Page 3 of 10
 by guest on January 30, 2014
http://ehjcimaging.oxfordjournals.org/
D
ow
nloaded from
 
Derivation of the partition coefficient and ECV
Myocardial l and ECV were also calculated at all time points. These
measures were derived from pre- and post-contrast myocardial
T1 values corrected for blood-pool T1 (measured at the mid-
cavity, Figure 1) and haematocrit (sampled at the time of CMR),
according to:
l = DR1myocardium/DR1blood pool,where R1 = 1/T1 (1)
ECV = (1 − hematocrit) × l (2)
Assessing myocardial T1 in multiple segments
Using a standardized approach, the basal, mid-cavity, and apical T1
maps were divided into segments according to the standard
17-segment model recommended by the American College of Cardi-
ology/American Heart Association.30 We excluded the true apex
because it was not possible to avoid partial volume effects. ROI were
drawn in each of the 16 segments on the pre-contrast T1 map and sub-
sequently, copied onto the post-contrast T1 map at the optimal time
point established from the above analysis (Figure 1B). Pre- and post-
contrast myocardial T1, l, and ECV values were assessed in each
segment of the left ventricle.
Comparison of T1 measures
Reproducibility analyses: intra-, inter-observer,
and scan–rescan
We established the reproducibility of our image analysis technique and
of the different T1 measures from a random sample of five healthy
volunteers and five patients with aortic stenosis. In assessing intra-obser-
ver reproducibility, a single observer repeated analysis after an interval of
.2 weeks to minimize recall bias. For inter-observer reproducibility, two
independent observers performed separate blinded analyses.
Scan–rescan reproducibility was assessed in 10 healthy volunteers.
Repeat scans were performed at least7 days after the first scan and haem-
atocrit samples were collected on both scan days. Images were analysed
as above by a single observer.
Statistical analysis
A formal sample size estimation was not performed because this was
an exploratory study to optimize a novel technique and to determine
the T1-derivedmeasurewith the mostpotential to assess diffuse myocar-
dial fibrosis.
The distribution of all continuous variables was assessed for normality
using the Shapiro–Wilk test. Continuous variables were presented as
mean+ standard deviation or median with inter-quartile range as
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline clinical, echocardiographic and CMR characteristics
Healthy volunteers Aortic stenosis P value
Clinical
Males, n (%) 10 (50) 10 (50) 1.00
Median age, years (IQR) 55 (22, 65) 71 (53, 75) ,0.01
Hypertension, n (%) 0 12 (60) –
Diabetes mellitus, n (%) 0 3 (15) –
Coronary artery disease, n (%) 0 4 (20) –
Systolic blood pressure, mmHg 140+12 153+25 0.05
Heart rate, beats/min 67+11 62+10 0.14
Haematocrit 0.41+0.03 0.39+0.04 0.05
Medications
Aspirin, n (%) 0 6 (30) –
ACEI/ARB, n (%) 0 6 (30) –
Beta blockers, n (%) 0 3 (15) –
Statin therapy, n (%) 0 8 (40) –
Echocardiography
Aortic valve area, cm2 2.4+0.6 1.2+0.6 , 0.01
Mean pressure gradient, mmHg 4+1 25+16 , 0.01
Peak velocity, m/s 1.4+0.2 3.3+0.9 , 0.01
Mean e′, cm/s 10.7+4.1 6.5+2.5 , 0.01
Median E/e′ (IQR) 7.1 (6.0, 8.4) 12.3 (8.6, 17.0) 0.03
Cardiac magnetic resonance
Indexed EDV, mL/m2 76+14 74+18 0.65
Indexed ESV, mL/m2 28+7 23+9 0.07
Stroke volume, mL/m2 48+8 51+12 0.43
Indexed LV mass, g/m2 67+14 81+18 , 0.01
LV mass/EDV, g/mL 0.88+0.10 1.11+0.20 ,0.01
EDV, end diastolic volume; ESV, end systolic volume; IQR, interquartile range; ACEI, angiotensin-converting enzyme inhibitors; ARB angiotensin receptor blockers.
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appropriate. Comparison of continuous variables was performed using
Student’s t-test or the Mann–Whitney U test for non-parametric data.
Categorical variables were expressed as percentages and compared
using the x2 test. In all T1-derived measures, we compared the values
across all the segments using one-way analysis of variance (ANOVA)
with post hoc Bonferroni adjustment. We examined the potential influ-
ence of heart rate and age on T1 measures using univariate linear analysis
and adjusted for the effects of age and haematocrit using multivariate
linear regression.
Reproducibility analysis (intra-, inter-observer, and scan–rescan) was
performed using intra-class correlation coefficients (ICC). ICC values
between 0.50 and 0.75 indicated moderate reliability and values .0.75
goodreliability. Forclinicalmeasures, excellent ICCsof.0.90arerequired
to ensure sufficient reliability.31 Fixed and proportional biases with 95%
limits of agreement were assessed using Bland–Altman analyses.
All statistical analyses were performed using GraphPad Prism
(GraphPad Software, Inc., San Diego, CA, USA) and SPSS version 19
(SPSS, Inc.,Chicago, IL). A two-sided P, 0.05 wasconsidered statistically
significant.
Results
Patients with aortic stenosis were older than healthy volunteers
(median age 75 vs. 55 years, P, 0.01) and there were an equal
number of males and females (Table 1). On average, they had moder-
ate aortic stenosis (a mean aortic valve area of 1.2+0.6 cm2; peak
aortic valve velocity 3.3+0.9 m/s) with an increased left ventricular
mass index and indices of diastolic dysfunction compared with
healthy volunteers (Table 1).
A total of 1215 myocardial segments were analysed (606 in healthy
volunteers and 609 in patients with aortic stenosis). 5.1% of segments
were rejected because of artefact.
Influence of heart rate and age on T1
measures
Across the range of heart rates in our study, there was no correlation
between heart rate and pre-contrast myocardial T1 (r ¼ 20.23,
Figure2 Variation of different T1 measures with time. (A) Myocardium and blood-pool T1. Post-contrast T1 values are dramatically reduced with
the administration of contrast, followed by an exponential increase in values towards baseline. Significant changes in T1 were observed in the first
15 min following contrast administration, while a plateau phase was observed between 15 and 30 min where values remained relatively unchanged.
(B) Change in T1 relaxation rates (DR1) in the myocardium and blood pool. During the first 15 min, significant changes inDR1 values were observed
in the myocardium and blood pool. This was followed by values that remained relatively stable between 15 and 30 min. (C andD) Partition coefficient
and ECV. Both measures were constant at all the time points examined, suggesting contrast equilibrium between the blood pool and myocardium
occurs as early as 2 min. *Denotes significant difference in values (P, 0.05) between the two adjacent time points
T1 mapping at 3T in patients with AS Page 5 of 10
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P ¼ 0.16), suggesting that incomplete restoration of magnetization
due to fast heart rates and long T1 values was not an important
factor. In healthy volunteers (age range 19–75) there was no
correlation between age and any of the T1 measures investigated
(pre-contrast myocardial T1, r ¼ 20.09, P ¼ 0.70; post-contrast
myocardial T1, r ¼ 20.25, P ¼ 0.29; l, r ¼ 0.16, P ¼ 0.52; and
ECV, r ¼ 0.25, P ¼ 0.29).
Effects of time on post-contrast T1 values
Post-contrast T1 values in the blood pool and myocardium were
lower than pre-contrast values, and demonstrated an exponential
return to baseline with time (Figure 2; Supplementary data online).
In particular, the initial 15-min post-contrast MOLLIswere character-
ized by rapid changes in T1 values but thereafter the relaxation curve
appeared to plateau such that subsequent changes were minimal.
Indeed, T1 values at 20 min did not differ significantly from those at
15 and 30 min (Figure 2). On this basis, 20 min was the time point
used for subsequent comparisons.
Interestingly, l or ECV values were constant at all time points
evaluated, reflecting a constant relationship between the myocardial
and blood-pool T1 relaxation times (Figure 2).
Regional variation in T1 measures
In healthy volunteers, there was no variation in any of the T1
measures across the 16 segments of the left ventricle (P. 0.1 in all
measures; all pairwise comparisons with Bonferroni corrections),
with similar results demonstrated in patients with aortic stenosis
(Figure 3). Specifically, there were no differences across any of the
myocardial slices or between segments within the same slice
(P. 0.1 for all measures; all pairwise comparisons with Bonferroni
corrections). Indeed, T1 measures in the mid-cavity were represen-
tative of those assessed across the entire left ventricular myocardium
(l 0.46+0.03 vs. 0.46+0.03, P ¼ 1.00; ECV 28.4+ 1.7 vs. 28.3+
Figure3 Variation in the different T1 measures across the left ventricular myocardium in patients with aortic stenosis. There were no differences
in the pre- (A) or post-contrast (B) myocardial T1, partition coefficient (C), and the ECV values (D) across the 16 segments. ICC values were.0.90
for each myocardial segment
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1.9%, P ¼ 0.61). Thus, the mid-cavity myocardium was used for
subsequent comparisons.
Comparison of T1 measures
Reproducibility analysis: intra-, inter-observer,
and scan–rescan
Intra- and inter-observer reproducibilities were excellent for pre-
and post-contrast T1 values, with no fixed or proportional biases
and narrow limits of agreement (Table 2). However, scan–rescan
reproducibilities for pre- and post-contrast T1 values were modest
(ICC 0.72 and 0.56, respectively).
Conversely, all measures of reproducibility were excellent for l
and ECV. ICC values were. 0.90 with no fixed biases and narrow
confidence limits (Table 2). The scan–rescan variability was+ 3%.
Furthermore, the ICC values for both l and ECV were .0.90 in
each of the 16 myocardial segments.
Ability to differentiate patients with aortic stenosis
from healthy volunteers
Pre-contrast myocardial T1 values were similar in healthy volunteers
and patients with aortic stenosis (1180+28 vs. 1191+ 34 ms,
P ¼ 0.29) as were post-contrast T1 values (672+56 vs. 663+
43 ms, P ¼ 0.59; Figure 4A). However, l and ECV values were
higher in patients with aortic stenosis compared with healthy volun-
teers (l 0.46+0.03 vs. 0.44+0.03, P ¼ 0.02; ECV 28.3+1.7 vs.
26.0+1.6%, P, 0.001; Figure 4B; Supplementary data online),
with the latter appearing to offer better differentiation. The absolute
increase in the ECV values in patients with aortic stenosis was 2.1%
compared with healthy volunteers (95% CI: 0.6–3.6%, P ¼ 0.009)
after adjustment for age and haematocrit levels. Moreover, a correl-
ation was observed between ECV and diastolic function (ECV and E/
e′ r ¼ 0.63, P, 0.01; ECV and e′ r ¼ 20.50, P, 0.01), providing in-
direct support for increased myocardial fibrosis in patients with
aortic stenosis. The other T1-related measures did not demonstrate
such an association (P. 0.05 for all).
Discussion
Using a standardized methodology and patient cohort, we have
systematically compared commonly used T1 measures at multiple
time points and in multiple regions across the left ventricle. We
have shown that pre-contrast T1 was limited by an inability to
differentiate patients with aortic stenosis from healthy volunteers,
while post-contrast myocardial T1 lacked sufficient scan–rescan
reproducibility. In comparison,l and in particular ECV demonstrated
excellent reproducibility and were increased in patients with aortic
stenosis compared with healthy volunteers.
Over recent years, multiple T1-derived parameters have been
derived to assess diffuse myocardial fibrosis. We have attempted
to optimize and compare these different techniques at 3T using a
standardized technique with meticulous attention paid to avoid
blood pool and artefact. This approach demonstrated excellent
reproducibility, with respect to the entire ventricle and within
individual myocardial segments, indicating that both global and re-
gional T1 can be measured. Furthermore, pre- and post-contrast
T1, l, and ECV values did not vary across segments in the left
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ventricle. This is as anticipated given the diffuse distribution of
interstitial fibrosis.
We have also characterized the temporal variation of T1 mea-
sures. Post-contrast T1 demonstrated the characteristic exponential
increase back to baseline following gadolinium administration. The
rate of this recovery appears to be determined by the blood concen-
tration of gadolinium (equilibrium between blood pool and myocar-
dial T1 occurred as early as 2 min), which depends on its volume of
distribution and renal clearance. Whilst the first 15 min following in-
jection were characterized by large variations in myocardial and
blood-pool T1 values, a plateau phase ensued between 15 and
30 min during which T1 values were relatively constant. We there-
fore investigated whether meaningful comparisons could be made
between serial scans using post-contrast T1 values at 20 min. Unfor-
tunately, the scan–rescan reproducibility of post-contrast T1 was
modest. This is likely the consequence of inter-day variation in
Figure4 Ability of the T1 measures to differentiate patients with aortic stenosis from healthy volunteers. (A) There wasno significant difference in
pre- and post-contrast myocardial T1 values between healthy volunteers and patients with aortic stenosis. (B) Partition coefficient and ECV values
were significantly higher in patients with aortic stenosis compared with healthy volunteers. Results in mean+ SEM
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gadolinium pharmacokinetics relating to glomerular filtration rate,
the patient’s volume status and diet. Such variation will have had a
major impact on our post-contrast T1 values potentially obscuring
any differences attributable to diffuse fibrosis. Indeed, this is the
likely explanation for the lack of difference in values between patients
with aortic stenosis and healthy volunteers. Whilst complex kinetic
models have been developed in an attempt to correct for some of
these factors these are based upon multiple assumptions and data
acquired at 1.5 not 3T.32
An alternate T1 technique is thereforenecessary toovercomevar-
iations in gadolinium kinetics. One approach is pre-contrast myocar-
dial T1. In this study, pre-contrast myocardial T1 demonstrated
improved scan–rescan reproducibility; but, like post-contrast T1,
was unable to differentiate patients with aortic stenosis from
healthy volunteers. This probably reflects the reduced sensitivity of
pre-contrast techniques that rely on the inherent T1 properties of
healthy myocardium and fibrosis. In comparison, a recent study
demonstrated that pre-contrast myocardial T1 values (using the
shortened modified MOLLI sequence) were higher in patients with
severe aortic stenosis compared with healthy volunteers.10 Most
likely this reflects the more advanced disease state in their study
population. Indeed, there was no increase in the values amongst
their patients with moderate stenosis, who had a similar degree of
hypertrophy to our cohort (81+ 18 vs. 82+ 17 g/m2).
A second approach is to correct post-contrast myocardial T1
values for variation in the pharmacokinetics of gadolinium. l
appears to be an effective method by using a ratio of myocardial
and blood-pool T1 values. Indeed l demonstrated excellent repro-
ducibility, indicating that inter-day variation in gadolinium kinetics
can be accounted for by this approach. Furthermore, l values are
increased in patients with aortic stenosis compared with healthy
volunteers. This probably reflects the improved sensitivity of
contrast-enhanced techniques, based on the accumulation of gado-
linium in regions of fibrosis and the resultant shortening of T1.8
ECV translates l into a percentage of the myocardium affected by
diffuse fibrosis and is in many ways easier to conceptualize. Further-
more, it corrects for the effects of plasma volume, which can vary
considerably from day to day (perhaps accounting for some of the
scan–rescan variation in pre- and post-contrast T1 values). ECV
demonstrated excellent reproducibility in this study and appears to
further improve the differentiation between patients with aortic
stenosis and healthy volunteers.
Both l and ECV appear to possess all the necessary attributes for
the measurement of diffuse fibrosis at 3T. Interest surrounds such
techniques in the assessment of novel anti-fibrotic agents in aortic
stenosis 33 and our scan–rescan reproducibility will be of use when
estimating the required sample sizes for such studies. These will
require the excellent reproducibility provided by l and ECV to
ensure that any difference detected between scans is attributed to
the intervention. Moreover, the slowly progressive nature of fibrosis
means that any treatment differences are likely to be small, so that the
improved sensitivity of l and ECV in particular over pre-contrast T1
will also be important.
Study limitations
Bydesignwedid not recruit patients with end-stage aortic stenosis, as
we believe that T1 mapping will be more relevant to those with less
severe disease in whom myocardial fibrosis is more likely to be re-
versible with novel anti-fibrotic therapies. Unfortunately, this has
limited our ability to validate the various T1 measures against hist-
ology. However, good correlations for each technique have previ-
ously been established with histology, and supported in this study
by increased ECV and l in regions of LGE (Supplementary data
online). Furthermore, we have demonstrated a close association
betweenECVand markers of diastolic dysfunction. It is therefore rea-
sonable to assume that our T1-derived measures are markers of
diffuse myocardial fibrosis particularly, as we have carefully excluded
individuals with pathologies that might have confounded our results.
The patients with aortic stenosis were significantly older than
healthy volunteers in our study, but the differences in ECV and l
values between patients with aortic stenosis and healthy volunteers
were independent of age. This is also consistent with previous
studies.15,34
Scan–rescan reproducibility was only assessed in healthy volun-
teers, but not in patients with aortic stenosis. However, both patients
with aortic stenosis and healthy volunteers demonstrated similar T1
relaxation profiles in the myocardium and blood pool. Furthermore,
we did not observe any proportional bias in healthy volunteers.
Therefore, we believe that the scan–rescan reproducibility in
patients with aortic stenosis would be similar to that in healthy
volunteers.
Conclusions
In the CMR assessment of diffuse myocardial fibrosis, pre- and post-
contrast myocardial T1 have limitations. In contrast, l and in particu-
lar ECV demonstrate excellent reproducibility and an ability to differ-
entiate patients with aortic stenosis from healthy volunteers. Among
all the T1-derived measures evaluated, ECVappears to have the most
potential for the assessment of diffuse myocardial fibrosis at 3T.
Supplementary data
Supplementary data are available at European Heart Journal – Cardio-
vascular Imaging online.
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